Money‚ Politics

What to expect from China’s Party Congress

6 Oct 2022

This month’s quinquennial meeting will shed some light on President Xi Jinping’s policy priorities amid a slowing economy and Covid lockdowns. In this Viewsroom podcast, Breakingviews columnists offer pointers on what to watch for from this staged but critical political event.

China biotech has bitter U.S. pill to swallow

14 Sep 2022

Top contract drugmaker, WuXi Biologics, lost $7 bln in market value after U.S. President Biden vowed to cut dependence on foreign manufacturers. Building up domestic capacity will take years, so the selloff looks premature. Still, some form of decoupling is underway.

Jack Ma’s exit would smooth Ant’s IPO march

29 Jul 2022

The Alibaba founder may cede control of the fintech giant. This could mark a big advance in Ant's efforts to clean up governance and placate the officials who derailed its $37 bln float in 2020. A simpler ownership structure puts the company one step closer to a revived listing.

Health adds new letter to ESG for food groups

12 Jul 2022

Government crackdowns on junk food marketing will hurt sales for companies like Frosties maker Kellogg. And investors are increasingly pushing consumer groups to use independent criteria to show how healthy their grub is. Tougher scrutiny will mean a valuation slap for laggards.